The differential efficacy of pemetrexed according to NSCLC histology

A review of two phase III studies

Giorgio Scagliotti, Nasser Hanna, Frank Fossella, Katherine Sugarman, Johannes Blatter, Patrick Peterson, Lorinda Simms, Frances A. Shepherd

Research output: Contribution to journalArticle

563 Citations (Scopus)

Abstract

Background. Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. Methods. One study tested pemetrexed versus do-cetaxel in previously treated patients (n = 571) and the other tested cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced NSCLC. Cox proportional hazard models were used to test for covariate-adjusted treatment-by-histology interactions (THIs) for overall survival (os) and progression-free survival (PFs). For each histologic subgroup, the Kaplan-Meier method was used to estimate unadjusted within-arm medians, and Cox models were used to estimate covariate-ad- justed between-arm hazard ratios (HRs). Results. In both studies, treatment arms were well balanced for histology. THis were statistically significant (p < .005) for both OS and PFS. Nonsquamous patients treated with pemetrexed-based therapy experienced longer survival than the comparators (HR, 0.78 and 0.84, respectively), whereas squamous patients had shorter survival (HR, 1.56 and 1.23, respectively). Whereas the efficacy of pemetrexed regimens differed according to histology, it did not differ for docetaxel or for cisplatin plus gemcitabine. Pemetrexed was well tolerated across histologic groups.

Original languageEnglish
Pages (from-to)253-263
Number of pages11
JournalOncologist
Volume14
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Pemetrexed
Non-Small Cell Lung Carcinoma
Histology
gemcitabine
Cisplatin
docetaxel
Proportional Hazards Models
Survival
Disease-Free Survival
Therapeutics
Drug Therapy

Keywords

  • Adenocarcinoma
  • Large cell carcinoma
  • Non-small cell lung cancer
  • Nonsquamous histology
  • Pemetrexed
  • Squamous cell carcinoma
  • Thymidylate synthase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., ... Shepherd, F. A. (2009). The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. Oncologist, 14(3), 253-263. https://doi.org/10.1634/theoncologist.2008-0232

The differential efficacy of pemetrexed according to NSCLC histology : A review of two phase III studies. / Scagliotti, Giorgio; Hanna, Nasser; Fossella, Frank; Sugarman, Katherine; Blatter, Johannes; Peterson, Patrick; Simms, Lorinda; Shepherd, Frances A.

In: Oncologist, Vol. 14, No. 3, 03.2009, p. 253-263.

Research output: Contribution to journalArticle

Scagliotti, G, Hanna, N, Fossella, F, Sugarman, K, Blatter, J, Peterson, P, Simms, L & Shepherd, FA 2009, 'The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies', Oncologist, vol. 14, no. 3, pp. 253-263. https://doi.org/10.1634/theoncologist.2008-0232
Scagliotti, Giorgio ; Hanna, Nasser ; Fossella, Frank ; Sugarman, Katherine ; Blatter, Johannes ; Peterson, Patrick ; Simms, Lorinda ; Shepherd, Frances A. / The differential efficacy of pemetrexed according to NSCLC histology : A review of two phase III studies. In: Oncologist. 2009 ; Vol. 14, No. 3. pp. 253-263.
@article{1f7127f3301544e3a7718f2dc4eaea41,
title = "The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies",
abstract = "Background. Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. Methods. One study tested pemetrexed versus do-cetaxel in previously treated patients (n = 571) and the other tested cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced NSCLC. Cox proportional hazard models were used to test for covariate-adjusted treatment-by-histology interactions (THIs) for overall survival (os) and progression-free survival (PFs). For each histologic subgroup, the Kaplan-Meier method was used to estimate unadjusted within-arm medians, and Cox models were used to estimate covariate-ad- justed between-arm hazard ratios (HRs). Results. In both studies, treatment arms were well balanced for histology. THis were statistically significant (p < .005) for both OS and PFS. Nonsquamous patients treated with pemetrexed-based therapy experienced longer survival than the comparators (HR, 0.78 and 0.84, respectively), whereas squamous patients had shorter survival (HR, 1.56 and 1.23, respectively). Whereas the efficacy of pemetrexed regimens differed according to histology, it did not differ for docetaxel or for cisplatin plus gemcitabine. Pemetrexed was well tolerated across histologic groups.",
keywords = "Adenocarcinoma, Large cell carcinoma, Non-small cell lung cancer, Nonsquamous histology, Pemetrexed, Squamous cell carcinoma, Thymidylate synthase",
author = "Giorgio Scagliotti and Nasser Hanna and Frank Fossella and Katherine Sugarman and Johannes Blatter and Patrick Peterson and Lorinda Simms and Shepherd, {Frances A.}",
year = "2009",
month = "3",
doi = "10.1634/theoncologist.2008-0232",
language = "English",
volume = "14",
pages = "253--263",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "3",

}

TY - JOUR

T1 - The differential efficacy of pemetrexed according to NSCLC histology

T2 - A review of two phase III studies

AU - Scagliotti, Giorgio

AU - Hanna, Nasser

AU - Fossella, Frank

AU - Sugarman, Katherine

AU - Blatter, Johannes

AU - Peterson, Patrick

AU - Simms, Lorinda

AU - Shepherd, Frances A.

PY - 2009/3

Y1 - 2009/3

N2 - Background. Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. Methods. One study tested pemetrexed versus do-cetaxel in previously treated patients (n = 571) and the other tested cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced NSCLC. Cox proportional hazard models were used to test for covariate-adjusted treatment-by-histology interactions (THIs) for overall survival (os) and progression-free survival (PFs). For each histologic subgroup, the Kaplan-Meier method was used to estimate unadjusted within-arm medians, and Cox models were used to estimate covariate-ad- justed between-arm hazard ratios (HRs). Results. In both studies, treatment arms were well balanced for histology. THis were statistically significant (p < .005) for both OS and PFS. Nonsquamous patients treated with pemetrexed-based therapy experienced longer survival than the comparators (HR, 0.78 and 0.84, respectively), whereas squamous patients had shorter survival (HR, 1.56 and 1.23, respectively). Whereas the efficacy of pemetrexed regimens differed according to histology, it did not differ for docetaxel or for cisplatin plus gemcitabine. Pemetrexed was well tolerated across histologic groups.

AB - Background. Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. Methods. One study tested pemetrexed versus do-cetaxel in previously treated patients (n = 571) and the other tested cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced NSCLC. Cox proportional hazard models were used to test for covariate-adjusted treatment-by-histology interactions (THIs) for overall survival (os) and progression-free survival (PFs). For each histologic subgroup, the Kaplan-Meier method was used to estimate unadjusted within-arm medians, and Cox models were used to estimate covariate-ad- justed between-arm hazard ratios (HRs). Results. In both studies, treatment arms were well balanced for histology. THis were statistically significant (p < .005) for both OS and PFS. Nonsquamous patients treated with pemetrexed-based therapy experienced longer survival than the comparators (HR, 0.78 and 0.84, respectively), whereas squamous patients had shorter survival (HR, 1.56 and 1.23, respectively). Whereas the efficacy of pemetrexed regimens differed according to histology, it did not differ for docetaxel or for cisplatin plus gemcitabine. Pemetrexed was well tolerated across histologic groups.

KW - Adenocarcinoma

KW - Large cell carcinoma

KW - Non-small cell lung cancer

KW - Nonsquamous histology

KW - Pemetrexed

KW - Squamous cell carcinoma

KW - Thymidylate synthase

UR - http://www.scopus.com/inward/record.url?scp=64049115311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64049115311&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2008-0232

DO - 10.1634/theoncologist.2008-0232

M3 - Article

VL - 14

SP - 253

EP - 263

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 3

ER -